Cargando…
Low Abundance of Circulating Tumor DNA in Localized Prostate Cancer
PURPOSE: Despite decreased screening-based detection of clinically insignificant tumors, most diagnosed prostate cancers are still indolent, indicating a need for better strategies for detection of clinically significant disease before treatment. We hypothesized that patients with detectable circula...
Autores principales: | Hennigan, S. Thomas, Trostel, Shana Y., Terrigino, Nicholas T., Voznesensky, Olga S., Schaefer, Rachel J., Whitlock, Nichelle C., Wilkinson, Scott, Carrabba, Nicole V., Atway, Rayann, Shema, Steven, Lake, Ross, Sweet, Amalia R., Einstein, David J., Karzai, Fatima, Gulley, James L., Chang, Peter, Bubley, Glenn J., Balk, Steven P., Ye, Huihui, Sowalsky, Adam G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6746181/ https://www.ncbi.nlm.nih.gov/pubmed/31528835 http://dx.doi.org/10.1200/PO.19.00176 |
Ejemplares similares
-
MEIS1 down-regulation by MYC mediates prostate cancer development through elevated HOXB13 expression and AR activity
por: Whitlock, Nichelle C., et al.
Publicado: (2020) -
A case report of multiple primary prostate tumors with differential drug sensitivity
por: Wilkinson, Scott, et al.
Publicado: (2020) -
Metastatic Castration-Resistant Prostate Cancer Remains Dependent on Oncogenic Drivers Found in Primary Tumors
por: Einstein, David J., et al.
Publicado: (2021) -
Progression of prostate cancer reprograms MYC-mediated lipid metabolism via lysine methyltransferase 2A
por: Whitlock, Nichelle C., et al.
Publicado: (2022) -
AR-V7 biomarker testing for primary prostate cancer: The ongoing challenge of analytical validation and clinical qualification
por: Sowalsky, Adam G., et al.
Publicado: (2020)